Driving Long-Term Growth: IMDELLTRA™ Approval and Information Update Presentation

Driving Long-Term Growth:

IMDELLTRA Approval and

Inflammation Update

May 20, 2024

Safe Harbor Statement

This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward- looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

2 Provided May 20, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

Agenda

Murdo Gordon

Exec. VP, Global Commercial Operations, Amgen

Opening ● IMDELLTRA

Jay Bradner, MD

Exec. VP, Research & Development, Amgen

IMDELLTRA ● Inflammation Strategy ● Rocatinlimab ● Conclusion

Jean-Charles Soria, MD

Sr. VP, Global Development Oncology, Amgen

IMDELLTRA

Susan Sweeney

Sr. VP, Global Marketing, Access Capabilities, Amgen

TEZSPIRE®

Primal Kaur, MD

VP, Global Development, Inflammation, Amgen

TEZSPIRE® ● AMG 104

3 Provided May 20, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

Four Therapeutic Area Pillars Driving Long-term Growth

GENERAL
MEDICINE	ONCOLOGY	INFLAMMATION	RARE DISEASE

Y

Marketed Products

Innovative Pipeline

Biosimilars

4 Provided May 20, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

IMDELLTRA for Patients with Advanced Small Cell Lung Cancer

IMDELLTRA Approved for the Treatment of Adult Patients with Extensive Stage SCLC with Disease Progression On or After Platinum-Based Chemotherapy

• First highly selective mechanism of action in SCLC
• First medicine with clinically meaningful and unprecedented efficacy in advanced ES-SCLC*
• • 40% overall response rate*
  • 9.7 month median duration of response*
  • 14.3 month median overall survival*
• First bispecific T-cell engager therapy for a major solid tumor
• Rapidly advancing into earlier treatment lines with robust clinical development program

SCLC, small cell lung cancer; ES-SCLC,extensive-stage small cell lung cancer.

*Based on results from the Phase 2 DeLLphi-301 clinical trial that evaluated IMDELLTRATM in patients with SCLC who had failed two or more prior lines of treatment.

6 Provided May 20, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

Patients with SCLC are at Risk for Rapid Disease Progression1

2/3

of patients with SCLC are diagnosed with EXTENSIVE-STAGE disease2

7%

5-YEAR SURVIVAL RATE for patients with invasive disease3,*

• 75%

of patients with

SCLC EXPERIENCE DISEASE PROGRESSION1

SCLC, small cell lung cancer; SEER, Surveillance, Epidemiology, and End Results.

*Based on SEER 9 in patients diagnosed with invasive small cell cancer of the lung and bronchus between 2010 and 2016.3

1. Rudin CM, et al. Nat Rev Dis Primers. 2021;7:3. 2. Sabari JK, et al. Nat Rev Clin Oncol. 2017;14:549-561.3. National Cancer Institute. www.cancer.gov. Accessed March 26, 2024.

7 Provided May 20, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

World Overall Survival in ES-SCLC is Poor Across Geographies

Median Real World Overall Survival (95% CI) in months

1L	8.1 (7.9-8.2)	8.1 (7.9-8.2)	8.6 (8.2-9.0)	11.3	(9.7-12.2)	8.4 (8.1-8.7)
n=4308	n=14700	n=1526		n=343	n=2237
2L	4.8 (4.5-5.1)	5.6 (5.3-5.8)	5.6 (4.9-6.2)	6.9	(6.3-7.9)	4.9 (4.5-5.4)
n=1822	n= 3220	n= 589		n= 202	n=981
3L	4.1 (3.7-4.6)	5.0 (4.7-5.5)	4.5 (4.0-5.1)	5.1	(3.9-5.8)	4.4 (3.9-5.5)
n= 680	n=640	n=213		n=97	n=349

1L, front-line; 2L, second line; 3L, third-line; 95% CI, 95% confidence interval; SCLC, small cell lung cancer; ES-SCLC, extensive stage small cell lung cancer; RWE, real-world evidence. Methods: Kaplan Meier curves were regenerated using Engauge Digitizer Software. Final combined graph was generated in R with standard ggplot package.

References: Mark Mitchell, Baurzhan Muftakhidinov and Tobias Winchen et al, "Engauge Digitizer Software." Webpage: http://markummitchell.github.io/engauge-digitizer, Last Accessed: February 6, 2024

Amgen sponsored RWE studies: United States (Study 20220192); United Kingdom (20220199); Spain (20230020); South Korea (20230021); Taiwan (20210117)

8 Provided May 20, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

The First and Only DLL3-Targeting BiTE® Therapy that Activates the Patient's Own T-Cells to Attack DLL3-Expressing Cells1

TARGET

IMDELLTRA targets the DLL3 antigen while simultaneously engaging the patient's own T-cells through the CD3 antigen1

ACTIVATE

The binding of IMDELLTRA results in the formation of a synapse between T-cells and DLL3-expressing cells, including tumor cells, leading to T-cell activation1

ATTACK

The activated T-cells cause release of inflammatory cytokines and lysis of DLL3-expressing cells1,*

• 85%-96%of patients with SCLC express DLL32,3,†,‡

DLL3 testing is not required for

treatment with IMDELLTRA 1

BiTE®, Bispecific T-cell Engager; CD, cluster of differentiation; DLL3, delta-like ligand 3; ES-SCLC,extensive-stage small cell lung cancer; SCLC, small cell lung cancer.

*IMDELLTRA had anti-tumor activity in mouse models of SCLC.1 † Based on a multicenter, international, noninterventional study of 1,050 patients with SCLC, with 1 specimen and evaluable DLL3 expression. DLL3 positivity

was based on immunohistochemistry staining with ≥ 25% of tumor cells that expressed DLL3. DLL3 staining defined as present if tumor cells showed punctate and/or diffuse cytoplasmic and/or partial or circumferential membranous staining.2

‡Based on the DeLLphi-301, phase 2, open-label study of 157 patients with ES-SCLC and an evaluable tumor-tissue sample. 151 out of 157 patients were DLL3-positive (96%). DLL3 expression was defined as detection of expression on more than 0% of tumor cells.3

1. IMDELLTRA (tarlatamab-dlle) prescribing information, Amgen. 2. Rojo F, et al. Lung Cancer. 2020;147:237-243. 3. Ahn M-J, et al. N Engl J Med. 2023;389:2063-2075.

9 Provided May 20, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

IMDELLTRA was Studied in Heavily Pretreated Patients with Poor Prognoses

Age

Median, years (min, max)	64	(35, 82)
≥ 65 years, n (%)	48	(48.0)
≥ 75 years, n (%)	10	(10.0)
Sex, n (%)
Male	71	(72.0)
Race, n (%)
Asian	41	(41.0)
White	57	(58.0)
Hispanic or Latino	1 (1.0)
ECOG status, n (%)
0	26 (26.0)
1	73	(74.0)
Metastatic at baseline, n (%)
Yes	96	(97.0)
No	3 (3.0)

Brain metastases at baseline, n (%)

Yes	22	(22.0)
No		77	(78.0)
Prior therapy, n (%)
Prior platinum-based	99	(100)
chemotherapy
Prior topoisomerase I		50	(51.0)
inhibitor therapy
Prior anti-PD-L(1) therapy	73	(74.0)
Smoking history at baseline, n (%)
Never	8 (8.0)
Former/Current	91 (92.0)

74%

22%

received prior anti-PD-(L)1 therapy

had brain metastases

BICR, blinded independent central review; ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death ligand. *Based on patients in the study who received at least 1 dose of IMDELLTRA 10 mg and had measurable disease at baseline per BICR.

1. IMDELLTRA (tarlatamab-dlle) prescribing information, Amgen.

10 Provided May 20, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.